Page 1 of 2

Montelukast linked to suicidality and other psychiatric adverse reactions

Montelukast sodium ( Singulair ), a leukotriene-receptor antagonist, is indicated for the prophylaxis and chronic treatment of asthma in patients 2 years of age and older. It is also indicated for the relief of symptoms of seasonal allergic rhinitis in patients 15 years of age and older when other t...
Read Article

Neuropsychiatric events with leukotriene inhibitors: Montelukast, Zafirlukast and Zileuton

Neuropsychiatric events have been reported in some patients taking Montelukast ( Singulair ), Zafirlukast ( Accolate ), and Zileuton ( Zyflo and Zyflo CR ). The FDA ( Food and Drug Administration ) has requested that manufacturers include a precaution in the drug prescribing information. Monte...
Read Article

Asthma: possible link between Singulair and suicide

The FDA ( Food and Drug Administration ) is investigating a possible association between the use of Singulair ( Montelukast ) and behavior/mood changes, suicidality ( suicidal thinking and behavior ) and suicide. Singulair is a medicine in the drug class known as leukotriene receptor antagonists...
Read Article

Asthma: possible association between Singulair and behavior/mood changes, suicidality and suicide

The FDA ( Food and Drug Adminsitration ) is investigating a possible association between the use of Singulair ( Montelukast ) and behavior/mood changes, suicidality ( suicidal thinking and behavior ) and suicide. Singulair is a medicine in the drug class known as leukotriene receptor antagonist...
Read Article

Xyzal improves quality of life in children with allergic rhinitis

In a study, children aged 6 to 12 suffering from perennial allergic rhinitis, not only got fast relief of symptoms when they took the once daily antihistamine, Xyzal ( Levocetirizine ), they also benefited from improved quality of life. Results from the first study to investigate the impact of a ...
Read Article

FDA approves Singulair for perennial allergic rhinitis

Fda ( Food and Drug Administration ) has approved Singulair ( Montelukast ) for the relief of symptoms of perennial allergic rhinitis ( PAR ), or indoor allergies, in adults and children six months of age and older. A convenient once-a-day tablet, Singulair has been proven to help relieve a broad...
Read Article

CRX-675 Phase I clinical trial for patients with allergic rhinitis

Preliminary results of the clinical trial of CRX-675, a toll-like receptor 4 ( TLR4 ) agonist, in subjects allergic to ragweed showed that the drug is safe. The study was a randomized, blinded, placebo-controlled trial of single doses of CRX-675 given intranasally prior to intranasal challenges ...
Read Article

New treatment guidelines for pregnant women with asthma

The National Asthma Education and Prevention Program (NAEPP) has issued the first new guidelines for managing asthma during pregnancy. The report reflects new medications that have emerged and updates treatment recommendations for pregnant women with asthma based on a systematic review of data on t...
Read Article

Products derived from bees: serious adverse reactions

Substances derived from bees include bee pollen, royal jelly and propolis. Bee pollen can come from a variety of plants and may include pollen to which people are commonly allergic ( e.g., ragweed pollen ). Royal jelly consists of the secretions of the hypopharyngeal and mandibular glands of worke...
Read Article

FDA approves Asmanex for once-daily treatment of asthma

The FDA ( Food and Drug Administration ) has approved the use of Asmanex Twisthaler 220 mcg ( Mometasone furoate inhalation powder ) for the first-line maintenance treatment of asthma as preventive therapy in patients 12 years of age and older. Clinical studies with Asmanex have shown improveme...
Read Article